Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03847428 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Study acronym: EMERALD-2
StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 54 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Trial completed Study completion date changed from estimate of May 31, 2027 to Jul 27, 2026 · Eligibility criteria expanded, about 13 words · Secondary endpoints: details revised at 1 of 5 entries Show 3 more changesShow less
    • Study completion date changed from estimate of May 31, 2027 to Jul 27, 2026
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 1 of 5 entries
  2. Primary completion date changed from estimate of May 29, 2026 to May 15, 2026v53
  3. Site details revised at 1 of 217 sitesv52
  4. 2 versions Re-verified since Sep 4, 2025, no change to tracked fieldsv50-v51
  5. Site details revised at 2 of 217 sitesv49
Show 44 earlier versionsHide 44 earlier versions
  1. Site details revised at 1 of 217 sitesv48
  2. Study sites: 216 to 217v47
  3. Study sites: 214 to 216v46
  4. Primary completion date: Aug 30, 2024 to May 29, 2026 Completion date: Aug 31, 2025 to May 31, 2027v45 Show 1 more changeShow less
    • Completion date: Aug 31, 2025 to May 31, 2027
  5. Site details revised at 1 of 214 sitesv44
  6. Study sites: 213 to 214v43
  7. Re-verified, no change to tracked fieldsv42
  8. Primary completion date: May 31, 2023 to Aug 30, 2024 Completion date: May 31, 2024 to Aug 31, 2025v41 Show 1 more changeShow less
    • Completion date: May 31, 2024 to Aug 31, 2025
  9. Re-verified, no change to tracked fieldsv40
  10. Site details revised at 1 of 213 sitesv39
  11. Enrollment target: 877 to 908 Study sites: 215 to 213 · Primary completion date: Jun 5, 2023 to May 31, 2023v38 Show 2 more changesShow less
    • Study sites: 215 to 213
    • Primary completion date: Jun 5, 2023 to May 31, 2023
  12. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 888 to confirmed 877 · Study sites: 267 to 215 · Primary completion date: May 31, 2023 to Jun 5, 2023v37 Show 3 more changesShow less
    • Enrollment target: estimated 888 to confirmed 877
    • Study sites: 267 to 215
    • Primary completion date: May 31, 2023 to Jun 5, 2023
  13. Site details revised at 1 of 267 sitesv36
  14. Study sites: 265 to 267v35
  15. Study sites: 268 to 265v34
  16. Study sites: 250 to 268v33
  17. Site details revised at 3 of 250 sitesv32
  18. Study sites: 247 to 250v31
  19. Study sites: 248 to 247v30
  20. Study sites: 244 to 248v29
  21. Study sites: 256 to 244v28
  22. Secondary endpoints revised (5) Site details revised at 64 of 256 sites · Eligibility criteria shortened, about 2 wordsv27 Show 2 more changesShow less
    • Site details revised at 64 of 256 sites
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  23. Study sites: 251 to 256v26
  24. Study sites: 249 to 251v25
  25. Primary completion date: Sep 30, 2022 to May 31, 2023 Study sites: 228 to 249 · Completion date: Sep 19, 2023 to May 31, 2024v24 Show 2 more changesShow less
    • Study sites: 228 to 249
    • Completion date: Sep 19, 2023 to May 31, 2024
  26. Study sites: 217 to 228v23
  27. Study sites: 201 to 217v22
  28. Study sites: 191 to 201v21
  29. Study sites: 183 to 191v20
  30. Study sites: 181 to 183v19
  31. Site details revised at 10 of 181 sitesv18
  32. Study sites: 180 to 181v17
  33. Study sites: 179 to 180v16
  34. Study sites: 181 to 179v15
  35. Study sites: 179 to 181 Primary completion date: Jun 29, 2022 to Sep 30, 2022 · Completion date: Jun 16, 2023 to Sep 19, 2023v14 Show 2 more changesShow less
    • Primary completion date: Jun 29, 2022 to Sep 30, 2022
    • Completion date: Jun 16, 2023 to Sep 19, 2023
  36. Study sites: 175 to 179v13
  37. Study sites: 168 to 175 Secondary endpoints: 6 to 5v12 Show 1 more changeShow less
    • Secondary endpoints: 6 to 5

    See this version in full on ClinicalTrials.gov ↗

  38. Study sites: 165 to 168v11
  39. Site details revised at 13 of 165 sitesv10
  40. Study sites: 163 to 165v9
  41. Study sites: 160 to 163v8
  42. Study sites: 152 to 160v7
  43. Study sites: 142 to 152v6
  44. Study sites: 132 to 142v5
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Liver Cancer
1,512 trials monitored
See 63 trials at risk
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
Trial Details
NCT Number NCT03847428
Lead Sponsor AstraZeneca
Conditions Hepatocellular Carcinoma
Enrollment 908 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov